Meta‐analysis evaluating apixaban in patients with atrial fibrillation and end‐stage renal disease requiring dialysis

Abstract

Abstract Background Warfarin is considered the primary oral anticoagulant for patients with atrial fibrillation and end‐stage renal disease (ESRD) requiring dialysis. Although warfarin can offer significant stroke prevention in this population, the accompanying major bleeding risks make warfarin nearly prohibitive. Apixaban was shown to be superior to warfarin in preventing stroke or systemic embolism, with a lower risk of bleeding and mortality in a large, randomized trial of individuals with mostly normal renal function but none with ESRD. Methods We systematically reviewed evidence comparing apixaban versus warfarin for atrial fibrillation in this population, and evaluated outcomes of stroke or systemic embolism, and major bleeding using random‐effects models. The main safety outcome was major bleeding, and the main effectiveness outcome was stroke or systemic embolism. Results We found five observational studies of 10 036 patients (2638 receiving apixaban, and 7398 receiving warfarin) meeting inclusion criteria. Pooled analysis demonstrated a significant reduction in major bleeding with apixaban as compared to warfarin (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.42–0.61; p < .0001). Apixaban was also associated with a reduction in intracranial bleeding (OR 0.58, 95% CI 0.37–0.92; p = .02) and in gastrointestinal bleeding (OR 0.61, 95% CI 0.51–0.73; p < .0001). Furthermore, apixaban was associated with a reduction in stroke/systemic embolism (OR 0.64, 95% CI 0.50–0.82; p < .0001). Conclusion Apixaban was associated with superior outcomes and reduced adverse events compared to warfarin in observational studies of patients with atrial fibrillation on dialysis. Randomized controlled studies are needed to confirm these findings.

Keywords

• anticoagulation
• apixaban
• atrial fibrillation
• dialysis
• warfarin